For så vidt angår behandling af febrile patienter med neutropeni, vurderede CHMP, at anvendelsen af ciprofloxacin på trods af den manglende robusthed af de tilgængelige data (begrænset antal patienter i disse undersøgelser) stadig var almindeligt anerkendt i de faglige kredse og var blevet en del af den kliniske praksis.
With regards to the treatment of febrile patients with neutropenia, the CHMP considered that, despite the lack of robustness of the available data (limited number of patients included in these studies), the use of ciprofloxacin remained well admitted in the scientific community and had become part of the clinical practice.